Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. Aclaris has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.

Company Growth (employees)
Type
Public
HQ
Malvern, US
Founded
2012
Size (employees)
31 (est)+73%
Aclaris Therapeutics was founded in 2012 and is headquartered in Malvern, US

Aclaris Therapeutics Office Locations

Aclaris Therapeutics has an office in Malvern
Malvern, US (HQ)
400 101 Lindenwood Dr

Aclaris Therapeutics Financials and Metrics

Aclaris Therapeutics Financials

USD

Revenue (Q3, 2017)

684 k

Gross profit (Q3, 2017)

231 k

Gross profit margin (Q3, 2017), %

34%

Net income (Q3, 2017)

(45.6 m)

EBIT (Q3, 2017)

(18.8 m)

Market capitalization (13-Nov-2017)

642.7 m
Aclaris Therapeutics's current market capitalization is $642.7 m.
USDFY, 2015FY, 2016

R&D expense

15.3 m33.5 m

General and administrative expense

5.3 m15.1 m

Operating expense total

20.7 m48.6 m

EBIT

(20.7 m)(48.6 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

684 k

Cost of goods sold

453 k

Gross profit

231 k

Gross profit Margin, %

34%
USDFY, 2015FY, 2016

Cash

9.9 m

Inventories

1.7 m

Current Assets

86.5 m

PP&E

360 k
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

13.1 m31.8 m17.8 m

Current Assets

86.8 m95.6 m85.6 m

PP&E

417 k434 k461 k

Total Assets

87.3 m96.1 m86.1 m
    USDFY, 2015FY, 2016

    Net Income

    (20.6 m)(48.1 m)

    Depreciation and Amortization

    90 k120 k

    Accounts Payable

    (359 k)1.8 m

    Cash From Operating Activities

    (20.4 m)(34.6 m)
    USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (13 m)(12.9 m)(10.7 m)(12.6 m)(27.4 m)(45.6 m)

    Depreciation and Amortization

    21 k50 k105 k

    Accounts Payable

    2 m3.3 m1.8 m831 k3.2 m3.1 m

    Cash From Operating Activities

    (6.9 m)(12.7 m)(22.7 m)(36.5 m)
      Show all financial metrics

      Aclaris Therapeutics Market Value History

      Aclaris Therapeutics's Web-traffic and Trends

      Aclaris Therapeutics Online and Social Media Presence

      Aclaris Therapeutics Company Life and Culture

      You may also be interested in